European Journal of Neurology 2013, 20: 1499–1507

doi:10.1111/ene.12303

EDITORIAL

Progress in European neurology 2012–2013

The past year has seen significant advances in neurology and neuroscience, and in the academic structures that support them. A review of events over 2012–2013 enables us to assess the progress of neurology as reported in this journal, and to reflect on forthcoming changes to the academic landscape of European neurology. We provide here a summary of articles published in the journal in 2012. These lists have proven popular as a ready resource to focus readers with specific interests. Stroke pathophysiology [1–23], the management of acute stroke [24–40], the general treatment and prevention of stroke [41–52] and measuring stroke outcomes [53–83] together constitute the most active area of research published in the journal. This is perhaps hardly surprising given that stroke is one of the commonest, disorders managed by neurologists and there is intense research activity to reduce the morbidity and mortality associated with it. Stroke prevention is probably the most rewarding area in this respect. Focus on specific treatable conditions such as hypertension, diabetes, hyperlipidaemia and atrial fibrillation and enhanced social awareness of the risks of smoking and obesity has considerable potential to reduce the burden of stroke. Unfortunately, reaching and treating those sections of the population most at risk of these is a challenge. Thus a parallel development of improving outcomes through improved acute treatment of stroke has been implemented. This too has paid dividends with national healthcare systems putting rapid access thrombolysis (now up to 4.5 h after onset of stroke) in place. Studies are now looking at the effectiveness of administration of thrombolysis by paramedical teams supported by mobile scanners and telemedicine. The management of multiple sclerosis has been transformed by the introduction of disease-modifying therapies, developed from an improved understanding of the pathogenesis of this disease [84–99]. As experience with these agents improves, their use in different patient groups becomes more refined and their potential long-term side effects better understood. Parkinson’s disease has likewise benefitted from significant advances in understanding pathogenesis, but has yet to develop any treatments that can slow the progression of neurodegeneration [100–130]. Developments in symptomatic therapies continue, including modifications in the delivery of current drugs to improve either adherence or motor control. The non-motor symptoms of Parkinson’s disease continue to attract a great

© 2013 The Author(s) European Journal of Neurology © 2013 EFNS

deal of attention in terms of assessing their contribution to disease burden and impaired quality of life, but the treatment of these remains limited. Other movement disorders including multiple system atrophy, progressive supranuclear palsy, essential tremor and dystonia have also benefitted from better insights into their aetiology, primarily through the application of modern genetics but also through more traditional pathology and biochemistry [131–149]. The dementias and neurodegenerative diseases in general represent a significant challenge to healthcare provision and considerable effort is now expended to understand pathogenesis and to develop new therapies – particularly those that would slow progression [150– 163]. There is an important aetiological overlap with the tauopathies and motor neuron diseases [164–178] and genetic advances in this area have implications for the role of tau in Alzheimer’s disease. Headache [179–188], epilepsy [189–197], infection [198–202], neuromuscular disease [203–217], trauma [218,219] and neuroinflammation [220–228] remain important practical diagnostic and management areas for the neurologist. In order to aid in the diagnosis and management of common neurological disorders, the European Federation of Neurological Societies has produced a series of guidelines and these continue to be developed and updated [229–235], providing an important resource and evidence base for clinicians. Finally, the journal is always keen to publish articles of general interest including those on the socioeconomic impact of neurological disease [236–244]. There will be changes to European neurology over 2013 2015. The two main European neurology societies, the European Neurological Society and the European Federation of Neurological Societies, will together merge to form the European Academy of Neurology (EAN). This development has been widely approved across neurology and by Europeans in particular. The leaders of the respective organizations who have worked towards this are to be applauded for their vision and tenacity in creating one society that will play a central role in neurology both in Europe and the world. I am pleased that the European Journal of Neurology will be the official journal of the EAN.

A. H. V. Schapira Editor-in-Chief European Journal of Neurology

1499

1500

Editorial

References Stroke

pathophophysiology

1. Fisher M. Cerebral microbleeds and white matter disease: separated at birth? Eur J Neurol 2012; 19: 2–3. 2. Yamada S, Saiki M, Satow T, et al. Periventricular and deep white matter leukoaraiosis have a closer association with cerebral microbleeds than age. Eur J Neurol 2012; 19: 98–104. 3. Gumbinger C, Krumsdorf U, Veltkamp R, Hacke W, Ringleb P. Continuous monitoring versus Holter ECG for detection of atrial fibrillation in patients with stroke. Eur J Neurol 2012; 19: 253–257. 4. Kim SJ, Choe YH, Park SJ, et al. Routine cardiac evaluation in patients with ischaemic stroke and absence of known atrial fibrillation or coronary heart disease: transthoracic echocardiography vs. multidetector cardiac computed tomography. Eur J Neurol 2012; 19: 317–323. 5. Wurster T, Stellos K, Geisler T, et al. Expression of stromal-cell-derived factor-1 (SDF-1): a predictor of ischaemic stroke? Eur J Neurol 2012; 19: 395–401. 6. Rueda-Clausen CF, Cordoba-Porras A, Bedoya G, et al. Increased plasma levels of total homocysteine but not asymmetric dimethylarginine in Hispanic subjects with ischemic stroke FREC-VI sub-study. Eur J Neurol 2012; 19: 417–425. 7. Kraemer M, Heinemann FM, Horn PA, et al. Inheritance of moyamoya disease in a Caucasian family. Eur J Neurol 2012; 19: 438–442. 8. Cha MJ, Kim YD, Nam HS, Kim J, Lee DH, Heo JH. Stroke mechanism in patients with non-valvular atrial fibrillation according to the CHADS2 and CHA2DS2VASc scores. Eur J Neurol 2012; 19: 473–479. 9. Sander D, Poppert H, Sander K, Etgen T. The role of intima-media-thickness, ankle-brachial-index and inflammatory biochemical parameters for stroke risk prediction: a systematic review. Eur J Neurol 2012; 19: 544–e36. 10. Metso AJ, Metso TM, Debette S, et al. ; for the CADISP group. Gender and cervical artery dissection. Eur J Neurol 2012; 19: 594–602. 11. Qiu C, Zhang Y, Bronge L, et al. Medial temporal lobe is vulnerable to vascular risk factors in men: a population-based study. Eur J Neurol 2012; 19: 876–883. 12. Hu GC, Hsieh SF, Chen YM, Hsu HH, Hu YN, Chien KL. Relationship of initial glucose level and all-cause death in patients with ischaemic stroke: the roles of diabetes mellitus and glycated hemoglobin level. Eur J Neurol 2012; 19: 884–891. 13. Lee DH, Kim J, Lee HS, et al. Low ankle-brachial index is a predictive factor for initial severity of acute ischaemic stroke. Eur J Neurol 2012; 19: 892–898. 14. Liman TG, Bohner G, Heuschmann PU, Scheel M, Endres M, Siebert E. Clinical and radiological differences in posterior reversible encephalopathy syndrome between patients with preeclampsia-eclampsia and other predisposing diseases. Eur J Neurol 2012; 19: 935–943. 15. Bejot Y. Understanding lacunar stroke: also an epidemiological challenge. Eur J Neurol 2012; 19: 1051– 1052.

16. Manso H, Krug T, Sobral J, et al. Evidence for epistatic gene interactions between growth factor genes in stroke outcome. Eur J Neurol 2012; 19: 1151–1153. 17. De Reuck J, Deramecourt V, Cordonnier C, et al. Detection of microbleeds in post-mortem brains of patients with frontotemporal lobar degeneration: a 7.0-Tesla magnetic resonance imaging study with neuropathological correlates. Eur J Neurol 2012; 19: 1355–1360. 18. Linthorst GE, Ginsberg L. Prevalence of Fabry disease in TIA/stroke cohorts. What defines Fabry disease? Eur J Neurol 2012; 19: 1383–1384. 19. Sarikaya H, Yilmaz M, Michael N, Miserez AR, Steinmann B, Baumgartner RW. Zurich Fabry study prevalence of Fabry disease in young patients with first cryptogenic ischaemic stroke or TIA. Eur J Neurol 2012; 19: 1421–1426. 20. Marquardt L, Baker R, Segal H, et al. Fabry disease in unselected patients with TIA or stroke: populationbased study. Eur J Neurol 2012; 19: 1427–1432. 21. Lee MJ, Park YG, Kim SJ, Lee JJ, Bang OY, Kim JS. Characteristics of stroke mechanisms in patients with medullary infarction. Eur J Neurol 2012; 19: 1433–1439. 22. Wagner I, Volbers B, Kloska S, Doerfler A, Schwab S, Staykov D. Sex differences in perihemorrhagic edema evolution after spontaneous intracerebral hemorrhage. Eur J Neurol 2012; 19: 1477–1481. 23. Wang HC, Lin YJ, Lin WC, et al. The value of serial plasma nuclear and mitochondrial DNA levels in acute spontaneous intra-cerebral haemorrhage. Eur J Neurol 2012; 19: 1532–1538.

Stroke

acute stroke

24. Mohr JP, Sciarra D. Improving the assessment of TIAs. Eur J Neurol 2012; 19: 1. 25. Engelter ST, Amort M, Jax F, et al. Optimizing the risk estimation after a transient ischaemic attack the ABCDE plus sign in circle score. Eur J Neurol 2012; 19: 55–61. 26. Sykora M, Diedler J, Poli S, et al. Association of nondiabetic hyperglycemia with autonomic shift in acute ischaemic stroke. Eur J Neurol 2012; 19: 84–90. 27. Deguchi I, Dembo T, Fukuoka T, et al. Usefulness of MRA-DWI mismatch in neuroendovascular therapy for acute cerebral infarction. Eur J Neurol 2012; 19: 114–120. 28. Caeiro L, Ferro JM, Figueira ML. Apathy in acute stroke patients. Eur J Neurol 2012; 19: 291–297. 29. Juvela S, Siironen J. Early cerebral infarction as a risk factor for poor outcome after aneurysmal subarachnoid haemorrhage. Eur J Neurol 2012; 19: 332–339. 30. Ebinger M, Scheitz JF, Kufner A, Endres M, Fiebach JB, Nolte CH. MRI-based intravenous thrombolysis in stroke patients with unknown time of symptom onset. Eur J Neurol 2012; 19: 348–350. 31. Nam HS, Cha MJ, Kim YD, et al. Use of a handheld, computerized device as a decision support tool for stroke classification. Eur J Neurol 2012; 19: 426–430. 32. Ntaios G, Egli M, Arsovska A, et al. An intravenous insulin protocol for strict glycemic control in acute ischaemic stroke. Eur J Neurol 2012; 19: 443–451. 33. Fluri F, Jax F, Amort M, et al. Significance of microbleeds in patients with transient ischaemic attack. Eur J Neurol 2012; 19: 522–524.

© 2013 The Author(s) European Journal of Neurology © 2013 EFNS

Editorial

34. Kumral E, Polat F, Uzunkopru C, Calli C, Kitis O. The clinical spectrum of intracerebral hematoma, hemorrhagic infarct, non-hemorrhagic infarct, and non-lesional venous stroke in patients with cerebral sinusvenous thrombosis. Eur J Neurol 2012; 19: 537–543. 35. Choi KH, Park MS, Kim JT, et al. The serum ferritin level is an important predictor of hemorrhagic transformation in acute ischaemic stroke. Eur J Neurol 2012; 19: 570–577. 36. Kaste M. Is there a future for neuroprotective agents in acute ischaemic stroke? Eur J Neurol 2012; 19: 797–798. 37. Liu X, Wang L, Wen A, et al. Ginsenoside-Rd improves outcome of acute ischaemic stroke a randomized, double-blind, placebo-controlled, multicenter trial. Eur J Neurol 2012; 19: 855–863. 38. Meretoja A, Strbian D, Putaala J, Kaste M, Tatlisumak T; for the Helsinki Stroke Thrombolysis Registry Group. Hemiplegia and thrombolysis. Eur J Neurol 2012; 19: 1235–1238. 39. Sobrino T, Blanco M, Perez-Mato M, Rodriguez-Yanez M, Castillo J. Increased levels of circulating endothelial progenitor cells in patients with ischaemic stroke treated with statins during acute phase. Eur J Neurol 2012; 19: 1539–1546. 40. Fuentes B, Martinez-Sanchez P, de Lecinana MA, et al. Efficacy of intravenous thrombolysis according to stroke subtypes: the Madrid Stroke Network data. Eur J Neurol 2012; 19: 1568–1574.

Stroke

treatment

41. Kraemer M, Berlit P, Diesner F, Khan N. What is the expert’s option on antiplatelet therapy in moyamoya disease? Results of a worldwide survey. Eur J Neurol 2012; 19: 163–167. 42. Martin-Schild S. tPA for stroke are we ready to remove the barriers? Eur J Neurol 2012; 19: 359. 43. Guillan M, Alonso-Canovas A, Garcia-Caldentey J, et al. Off-label intravenous thrombolysis in acute stroke. Eur J Neurol 2012; 19: 390–394. 44. Fuentes B, Martinez-Sanchez P, Alonso de Lecinana M, et al. ; on behalf of the Madrid Stroke Network. Diabetes and previous stroke: hazards for intravenous thrombolysis? Eur J Neurol 2012; 19: 587–593. 45. Davie CA. Anticoagulation in cerebral venous sinus thrombosis. Eur J Neurol 2012; 19: 933–934. 46. Misra UK, Kalita J, Chandra S, Kumar B, Bansal V. Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: a randomized controlled trial. Eur J Neurol 2012; 19: 1030– 1036. 47. Vergouwen MDI. Intravenous thrombolysis in ischaemic stroke secondary to cervical artery dissection: safe but not effective? Eur J Neurol 2012; 19: 1155–1156. 48. Qureshi AI. Cervical artery dissection is not a benign entity in the thrombolytic era. Eur J Neurol 2012; 19: 1157–1158. 49. Engelter ST, Dallongeville J, Kloss M, et al. Thrombolysis in cervical artery dissection – data from the Cervical Artery, Dissection and Ischaemic Stroke Patients (CADISP) database. Eur J Neurol 2012; 19: 1199–1206. 50. Dorado L, Millan M, Perez dl O, et al. Time to recanalization and risk of symptomatic intracerebral haemorrhage in patients treated with intravenous thrombolysis. Eur J Neurol 2012; 19: 1251–1255.

© 2013 The Author(s) European Journal of Neurology © 2013 EFNS

1501

51. Berghauser Pont LME, Dirven CMF, Dippel DWJ, Verweij BH, Dammers R. The role of corticosteroids in the management of chronic subdural hematoma: a systematic review. Eur J Neurol 2012; 19: 1397–1403. 52. Yoo SH, Kwon SU, Jo MW, Kang DW, Kim JS. Ageand weight-adjusted warfarin initiation nomogram for ischaemic stroke patients. Eur J Neurol 2012; 19: 1547– 1553.

Stroke

outcomes

53. Ward AB. A literature review of the pathophysiology and onset of post-stroke spasticity. Eur J Neurol 2012; 19: 21–27. 54. Viken JI, Samuelsson H, Jern C, Jood K, Blomstrand C. The prediction of functional dependency by lateralized and non-lateralized neglect in a large prospective stroke sample. Eur J Neurol 2012; 19: 128–134. 55. Banerjee A, Lip GYH. Improving the diagnosis and prognosis of atrial fibrillation in stroke: quo vadis? Eur J Neurol 2012; 19: 187–188. 56. van Dijk EJ, de Leeuw FE. Recovery after stroke: more than just walking and talking again. If you don’t look for it, you won’t find it. Eur J Neurol 2012; 19: 189–190. 57. Planton M, Peiffer S, Albucher JF, et al. Neuropsychological outcome after a first symptomatic ischaemic stroke with ‘good recovery’. Eur J Neurol 2012; 19: 212–219. 58. De Raedt S, Haentjens P, De Smedt A, et al. Prestroke use of beta-blockers does not affect ischaemic stroke severity and outcome. Eur J Neurol 2012; 19: 234–240. 59. Kwon JY, Kwon SU, Kang DW, Suh DC, Kim JS. Isolated lateral thalamic infarction: the role of posterior cerebral artery disease. Eur J Neurol 2012; 19: 265–270. 60. Hong HJ, Kim YD, Cha MJ, et al. Early neurological outcomes according to CHADS2 score in stroke patients with non-valvular atrial fibrillation. Eur J Neurol 2012; 19: 284–290. 61. Canovas D, Gil A, Jato M, de Miquel M, Rubio F. Clinical outcome of spontaneous non-aneurysmal subarachnoid hemorrhage in 108 patients. Eur J Neurol 2012; 19: 457–461. 62. Altieri M, Maestrini I, Mercurio A, et al. Depression after minor stroke: prevalence and predictors. Eur J Neurol 2012; 19: 517–521. 63. Wagner I, Volbers B, Hilz MJ, Schwab S, Doerfler A, Staykov D. Radiopacity of intracerebral hemorrhage correlates with perihemorrhagic edema. Eur J Neurol 2012; 19: 525–528. 64. Kononen M, Tarkka IM, Niskanen E, et al. Functional MRI and motor behavioral changes obtained with constraint-induced movement therapy in chronic stroke. Eur J Neurol 2012; 19: 578–586. 65. Streifler JY, Benderly M, Molshatzki N, Bornstein N, Tanne D. Off-hours admission for acute stroke is not associated with worse outcome a nationwide Israeli stroke project. Eur J Neurol 2012; 19: 643–647. 66. Roquer J, Cuadrado-Godia E, Rodriguez-Campello A, et al. Serum cholesterol levels and survival after rtPA treatment in acute stroke. Eur J Neurol 2012; 19: 648–654. 67. Yeh PS, Lin HJ, Chen PS, et al. Effect of statin treatment on three-month outcomes in patients with stroke-

1502

68.

69.

70.

71.

72.

73.

74.

75.

76.

77.

78.

79.

80.

81.

82.

83.

Editorial

associated infection: a prospective cohort study. Eur J Neurol 2012; 19: 689–695. Bejot Y, Jacquin A, Rouaud O, et al. One-year survival of demented stroke patients: data from the Dijon Stroke Registry, France (1985 2008). Eur J Neurol 2012; 19: 712–717. Cramer SC, Procaccio V, for the GAIN Americas and GAIN International Study Investigators. Correlation between genetic polymorphisms and stroke recovery: analysis of the GAIN Americas and GAIN International Studies. Eur J Neurol 2012; 19: 718–724. Koton S, Tashlykov V, Schwammenthal Y, et al. Cerebral artery calcification in patients with acute cerebrovascular diseases: determinants and long-term clinical outcome. Eur J Neurol 2012; 19: 739–745. Yang SY, Paek SH, Kim DG, Chung HT. Quality of life after radiosurgery for cerebral arteriovenous malformation patients who present with seizure. Eur J Neurol 2012; 19: 984–991. Mateen FJ, Carone M, Alam N, Streatfield PK, Black RE. A population-based case control study of 1250 stroke deaths in rural Bangladesh. Eur J Neurol 2012; 19: 999–1006. Fang XH, Wang WH, Zhang XQ, et al. Incidence and survival of symptomatic lacunar infarction in a Beijing population: a 6-year prospective study. Eur J Neurol 2012; 19: 1114–1120. Saarinen JT, Sillanpaa N, Rusanen H, et al. The midM1 segment of the middle cerebral artery is a cutoff clot location for good outcome in intravenous thrombolysis. Eur J Neurol 2012; 19: 1121–1127. Martinez-Martinez MM, Fernandez-Travieso J, Fuentes B, et al. Off-hour effects on stroke care and outcome in stroke centres. Eur J Neurol 2012; 19: 1140–1145. New PW, McFarlane CL. Retrospective case series of outcomes following spinal cord infarction. Eur J Neurol 2012; 19: 1207–1212. Huang KB, Ji Z, Wu YM, Wang SN, Lin ZZ, Pan SY. The prediction of 30-day mortality in patients with primary pontine hemorrhage: a scoring system comparison. Eur J Neurol 2012; 19: 1245–1250. Manwani B, McCullough LD. Estrogen in ischaemic stroke: the debate continues. Eur J Neurol 2012; 19: 1276–1277. Pappa T, Vemmos K, Mantzou E, Savvari P, Stamatelopoulos K, Alevizaki M. Estradiol levels predict shortterm adverse health outcomes in postmenopausal acute stroke women. Eur J Neurol 2012; 19: 1300–1304. Arntzen KA, Schirmer H, Johnsen SH, Wilsgaard T, Mathiesen EB. Carotid artery plaque progression and cognitive decline: the Tromso Study 1994 2008. Eur J Neurol 2012; 19: 1318–1324. Sommerfeld DK, Welmer AK. Pain following stroke, initially and at 3 and 18 months after stroke, and its association with other disabilities. Eur J Neurol 2012; 19: 1325–1330. Goswami RP, Karmakar PS, Ghosh A. Early seizures in first-ever acute stroke patients in India: incidence, predictive factors and impact on early outcome. Eur J Neurol 2012; 19: 1361–1366. Malmivaara K, Juvela S, Hernesniemi J, Lappalainen J, Siironen J. Health-related quality of life and costeffectiveness of treatment in subarachnoid haemorrhage. Eur J Neurol 2012; 19: 1455–1461.

Multiple sclerosis

general

84. Kargarfard M, Eetemadifar M, Mehrabi M, Maghzi AH, Hayatbakhsh MR. Fatigue, depression, and health-related quality of life in patients with multiple sclerosis in Isfahan, Iran. Eur J Neurol 2012; 19: 431– 437. 85. Feinstein A. Multiple sclerosis and cognitive dysfunction: how accurate are patients’ self-assessments? Eur J Neurol 2012; 19: 535–536. 86. van der Hiele K, Spliethoff-Kamminga NGA, Ruimschotel RP, Middelkoop HAM, Visser LH. The relationship between self-reported executive performance and psychological characteristics in multiple sclerosis. Eur J Neurol 2012; 19: 562–569. 87. Damasceno A, Von Glehn F, de Deus-Silva L, Damasceno BP. Monthly variation of multiple sclerosis activity in the southern hemisphere: analysis from 996 relapses in Brazil. Eur J Neurol 2012; 19: 660–662. 88. Giordano A, Ferrari G, Radice D, Randi G, Bisanti L, Solari A, on behalf of the POSMOS study. Healthrelated quality of life and depressive symptoms in significant others of people with multiple sclerosis: a community study. Eur J Neurol 2012; 19: 847–854. 89. Lalmohamed A, Bazelier MT, Van Staa TP, et al. Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study. Eur J Neurol 2012; 19: 1007–1014.

Multiple sclerosis

pathogenesis

90. Harirchian MH, Tekieh AH, Modabbernia A, et al. Serum and CSF PDGF-AA and FGF-2 in relapsing remitting multiple sclerosis: a case control study. Eur J Neurol 2012; 19: 241–247. 91. Dhooghe MB, Haentjens P, Nagels G, De Keyser J. Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis. Eur J Neurol 2012; 19: 616–624. 92. Baar~ nrnhielm M, Hedstrom AK, Kockum I, et al. Sunlight is associated with decreased multiple sclerosis risk: no interaction with human leukocyte antigenDRB1*15. Eur J Neurol 2012; 19: 955–962.

Multiple sclerosis

treatment

93. Lampl C, You X, Limmroth V. Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age. Eur J Neurol 2012; 19: 142–148. 94. Fox EJ, Sullivan HC, Gazda SK, et al. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol 2012; 19: 307–311. 95. West TW, Killestein J, Fox RJ. Natalizumab discontinuation: an increasingly tricky proposition. Eur J Neurol 2012; 19: 663–664. 96. Hassan A, Ahlskog JE, Rodriguez M, Matsumoto JY. Surgical therapy for multiple sclerosis tremor: a 12-year follow-up study. Eur J Neurol 2012; 19: 764–768. 97. Borriello G, Prosperini L, Mancinelli C, Gianni C, Fubelli F, Pozzilli C. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol 2012; 19: 783–787. 98. Rio J, Tintore M, Sastre-Garriga J, et al. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol 2012; 19: 899–904.

© 2013 The Author(s) European Journal of Neurology © 2013 EFNS

Editorial

99. Jensen PE, Sellebjerg F, Sondergaard HB, Sorensen PS. Correlation between anti-interferon-beta binding and neutralizing antibodies in interferon-beta-treated multiple sclerosis patients. Eur J Neurol 2012; 19: 1311–1317.

Parkinson’s disease

general

100. Elia AE, Dollenz C, Soliveri P, Albanese A. Motor features and response to oral levodopa in patients with Parkinson’s disease under continuous dopaminergic infusion or deep brain stimulation. Eur J Neurol 2012; 19: 76–83. 101. Pan PL, Song W, Shang HF. Voxel-wise meta-analysis of gray matter abnormalities in idiopathic Parkinson’s disease. Eur J Neurol 2012; 19: 199–206. 102. Tolosa E, Stern MB. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson’s disease. Eur J Neurol 2012; 19: 258– 264. 103. Bloem BR, Stocchi F. Move for change Part I: a European survey evaluating the impact of the EPDA Charter for People with Parkinson’s Disease. Eur J Neurol 2012; 19: 402–410. 104. Izawa MO, Miwa H, Kajimoto Y, Kondo T. Combination of transcranial sonography, olfactory testing, and MIBG myocardial scintigraphy as a diagnostic indicator for Parkinson’s disease. Eur J Neurol 2012; 19: 411–416. 105. Klostermann F. Intestinal levodopa infusion and COMT inhibition a promising link. Eur J Neurol 2012; 19: 795–796. 106. Nyholm D, Johansson A, Lennernas H, Askmark H. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. Eur J Neurol 2012; 19: 820–826. 107. Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B. Treatment for Helicobacter pylori infection and risk of Parkinson’s disease in Denmark. Eur J Neurol 2012; 19: 864–869. 108. Morley D, Selai C, Thompson A. The self-report Barthel Index: preliminary validation in people with Parkinson’s disease. Eur J Neurol 2012; 19: 927–929. 109. Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson’s disease. Eur J Neurol 2012; 19: 1079–1085. 110. Bauso DJ, Tartari JP, Stefani CV, Rojas JI, Giunta DH, Cristiano E. Incidence and prevalence of Parkinson’s disease in Buenos Aires City, Argentina. Eur J Neurol 2012; 19: 1108–1113. 111. Santos-Garcia D, Anon MJ, Fuster-Sanjurjo L, Fuente-Fernandez R. Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson’s disease leads to improvement in caregivers’ stress and burden. Eur J Neurol 2012; 19: 1261–1265. 112. Chen IC, Wu YR, Yang SJ, et al. ATXN8-62 G/A promoter polymorphism and risk of Taiwanese Parkinson’s disease. Eur J Neurol 2012; 19: 1462–1469. 113. Schapira AHV, Tan EK. Optimizing treatment for Parkinson’s disease. Eur J Neurol 2012; 19: 1483– 1486. 114. Gershanik O, Jenner P. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson’s disease. Eur J Neurol 2012; 19: 1502–1508.

© 2013 The Author(s) European Journal of Neurology © 2013 EFNS

Parkinson’s disease

1503

pathogenesis

115. Lohmann E, Dursun B, Lesage S, et al. Genetic bases and phenotypes of autosomal recessive Parkinson disease in a Turkish population. Eur J Neurol 2012; 19: 769–775. 116. Liu H, Wei L, Tao Q, et al. Decreased NURR1 and PITX3 gene expression in Chinese patients with Parkinson’s disease. Eur J Neurol 2012; 19: 870–875. 117. Jin L, Wang J, Jin H, et al. Nigral iron deposition occurs across motor phenotypes of Parkinson’s disease. Eur J Neurol 2012; 19: 969–976.

Parkinson’s disease

non-motor

118. Perez-Lloret S, Negre-Pages L, Ojero-Senard A, et al. , for the COPARK Study Group. Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson’s disease: preliminary analysis from the French COPARK cohort. Eur J Neurol 2012; 19: 28–37. 119. Chaudhuri RK, Martinez-Martin P, Rolfe KA, et al. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease. Eur J Neurol 2012; 19: 105–113. 120. Strutt AM, Simpson R, Jankovic J, York MK. Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson’s disease. Eur J Neurol 2012; 19: 121–127. 121. Pellicano C, Assogna F, Piras F, Caltagirone C, Pontieri FE, Spalletta G. Regional cortical thickness and cognitive functions in non-demented Parkinson’s disease patients: a pilot study. Eur J Neurol 2012; 19: 172–175. 122. Canesi M, Rusconi ML, Isaias IU, Pezzoli G. Artistic productivity and creative thinking in Parkinson’s disease. Eur J Neurol 2012; 19: 468–472. 123. Chiang HL, Huang YS, Chen ST, Wu YR. Are there ethnic differences in impulsive/compulsive behaviors in Parkinson’s disease? Eur J Neurol 2012; 19: 494–500. 124. Miah IP, Olde Dubbelink KT, Stoffers D, Deijen JB, Berendse HW. Early-stage cognitive impairment in Parkinson’s disease and the influence of dopamine replacement therapy. Eur J Neurol 2012; 19: 510–516. 125. Okubo H, Miyake Y, Sasaki S, et al. , the Fukuoka Kinki Parkinson’s Disease Study Group. Dietary patterns and risk of Parkinson’s disease: a case control study in Japan. Eur J Neurol 2012; 19: 681–688. 126. Friedman JH. Is fatigue in early Parkinson’s disease a minor inconvenience or major distress? The answer is yes! Eur J Neurol 2012; 19: 931–932. 127. Herlofson K, Ongre SO, Enger LK, Tysnes OB, Larsen JP. Fatigue in early Parkinson’s disease. Minor inconvenience or major distress? Eur J Neurol 2012; 19: 963– 968. 128. Gonzalez-Redondo R, Toledo J, Clavero P, et al. The impact of silent vascular brain burden in cognitive impairment in Parkinson’s disease. Eur J Neurol 2012; 19: 1100–1107. 129. Marshall DF, Strutt AM, Williams AE, Simpson RK, Jankovic J, York MK. Alternating verbal fluency performance following bilateral subthalamic nucleus deep brain stimulation for Parkinson’s disease. Eur J Neurol 2012; 19: 1525–1531. 130. Stefansdottir S, Gjerstad MD, Tysnes OB, Larsen JP. Subjective sleep problems in patients with early Parkinson’s disease. Eur J Neurol 2012; 19: 1575–1581.

1504

Editorial

Other movement disorders 131. Netravathi M, Pal PK, Indira Devi B. A clinical profile of 103 patients with secondary movement disorders: correlation of etiology with phenomenology. Eur J Neurol 2012; 19: 226–233. 132. Walterfang M, Macfarlane MD, Looi JCL, et al. Pontine-to-midbrain ratio indexes ocular-motor function and illness stage in adult Niemann Pick disease type C. Eur J Neurol 2012; 19: 462–467. 133. Pauls KAM, Timmermann L. Deep brain stimulation in pantothenate kinase associated neurodegeneration: challenges for the future. Eur J Neurol 2012; 19: 533– 534. 134. Lim BC, Ki CS, Cho A, et al. Pantothenate kinaseassociated neurodegeneration in Korea: recurrent R440P mutation in PANK2 and outcome of deep brain stimulation. Eur J Neurol 2012; 19: 556–561. 135. Rizzo G, Manners D, Vetrugno R, et al. Combined brain voxel-based morphometry and diffusion tensor imaging study in idiopathic restless legs syndrome patients. Eur J Neurol 2012; 19: 1045–1049. 136. Kim KW, Jhoo JH, Lee SB, et al. Increased striatal dopamine transporter density in moderately severe old restless legs syndrome patients. Eur J Neurol 2012; 19: 1213–1218. 137. Fuente-Fern+ındez R. The powerful pre-treatment effect: placebo responses in restless legs syndrome trials. Eur J Neurol 2012; 19: 1305–1310. 138. Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol 2012; 19: 1385–1396. 139. Josephs KA, Eggers SDZ, Jack CR, Whitwell JL. Neuroanatomical correlates of the progressive supranuclear palsy corticobasal syndrome hybrid. Eur J Neurol 2012; 19: 1440–1446.

Other movement disorders

essential tremor

140. Chuang WL, Lu CS, Huang YZ, Chen RS. Clinical characteristics of essential tremor in Taiwan: an exploratory-comparative study. Eur J Neurol 2012; 19: 135– 141. 141. Yu M, Ma K, Faust PL, et al. Increased number of Purkinje cell dendritic swellings in essential tremor. Eur J Neurol 2012; 19: 625–630. 142. Louis ED, Gerbin M, Viner AS. Color vision: a study of essential tremor cases versus normal controls. Eur J Neurol 2012; 19: 1136–1139. 143. Louis ED, Huey ED, Gerbin M, Viner AS. Depressive traits in essential tremor: impact on disability, quality of life, and medication adherence. Eur J Neurol 2012; 19: 1349–1354.

Other movement disorders

dystonia

144. Aoki KR. Editorial comment on ‘5 year experience with incobotulinumtoxinA (Xeomin((R))) the first botulinum toxin drug free of complexing proteins’. Eur J Neurol 2012; 19: 355–356. 145. Moore AP. Editorial comment on the use of botulinum toxin. Eur J Neurol 2012; 19: 357–358. 146. Dressler D. Five-year experience with incobotulinumtoxinA (Xeomin((R))): the first botulinum toxin drug

free of complexing proteins. Eur J Neurol 2012; 19: 385–389. 147. Skogseid IM, Ramm-Pettersen J, Volkmann J, Kerty E, Dietrichs E, Roste GK. Good long-term efficacy of pallidal stimulation in cervical dystonia: a prospective, observer-blinded study. Eur J Neurol 2012; 19: 610– 615. 148. Chen Y, Burgunder JM, Song W, Huang R, Shang HF. Assessment of D216H DYT1 polymorphism in a Chinese primary dystonia patient cohort. Eur J Neurol 2012; 19: 924–926. 149. Roubertie A, Mariani LL, Fernandez-Alvarez E, Doummar D, Roze E. Treatment for dystonia in childhood. Eur J Neurol 2012; 19: 1292–1299.

Alzheimer’s disease and other dementias 150. Virhammar J, Cesarini KG, Laurell K. The CSF tap test in normal pressure hydrocephalus: evaluation time, reliability and the influence of pain. Eur J Neurol 2012; 19: 271–276. 151. Voigt-Radloff S, Leonhart R, Schutzwohl M, et al. Dementia quality of life instrument construct and concurrent validity in patients with mild to moderate dementia. Eur J Neurol 2012; 19: 376–384. 152. Kim EJ, Cho SS, Jeong BH, et al. Glucose metabolism in sporadic Creutzfeldt Jakob disease: a statistical parametric mapping analysis of 18F-FDG PET. Eur J Neurol 2012; 19: 488–493. 153. Deng J, Lian Y, Shen C, et al. Adverse life event and risk of cognitive impairment: a 5-year prospective longitudinal study in Chongqing, China. Eur J Neurol 2012; 19: 631–637. 154. Cappa SF. Subjective cognitive complaints: not to be dismissed. Eur J Neurol 2012; 19: 665. 155. Martins IP, Mares I, Stilwell PA. How subjective are subjective language complaints. Eur J Neurol 2012; 19: 666–671. 156. Kume K, Kikukawa M, Hanyu H, et al. Telomere length shortening in patients with dementia with Lewy bodies. Eur J Neurol 2012; 19: 905–910. 157. Perry DC, Whitwell JL, Boeve BF, et al. Voxel-based morphometry in patients with obsessive-compulsive behaviors in behavioral variant frontotemporal dementia. Eur J Neurol 2012; 19: 911–917. 158. Wang S, Song J, Tan M, Albers KM, Jia J. Mitochondrial fission proteins in peripheral blood lymphocytes are potential biomarkers for Alzheimer’s disease. Eur J Neurol 2012; 19: 1015–1022. 159. Annweiler C, Fantino B, Schott AM, Krolak-Salmon P, Allali G, Beauchet O. Vitamin D insufficiency and mild cognitive impairment: cross-sectional association. Eur J Neurol 2012; 19: 1023–1029. 160. Rousseaux M, Renier J, Anicet L, Pasquier F, Mackowiak-Cordoliani MA. Gesture comprehension, knowledge and production in Alzheimer’s disease. Eur J Neurol 2012; 19: 1037–1044. 161. Sorbi S, Hort J, Erkinjuntti T, et al. , the EFNS Scientist Panel on Dementia and Cognitive Neurology. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol 2012; 19: 1159–1179. 162. Cotelli M, Manenti R, Alberici A, et al. Prefrontal cortex rTMS enhances action naming in progressive nonfluent aphasia. Eur J Neurol 2012; 19: 1404–1412.

© 2013 The Author(s) European Journal of Neurology © 2013 EFNS

Editorial

163. Filippi M, Agosta F, Barkhof F, et al. EFNS task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol 2012; 19: 1487–1501.

Motor neurone disease/amyotrophic lateral sclerosis 164. Klimpe S, Schule R, Kassubek J, Schols L, et al. Disease severity affects quality of life of hereditary spastic paraplegia patients. Eur J Neurol 2012; 19: 168–171. 165. The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, Hardiman O, Kollewe K, Morrison KE, Petri S, Pradat PF, Silani V, Tomik B, Wasner M, Weber M. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) revised report of an EFNS task force. Eur J Neurol 2012; 19: 360–75. 166. Wicks P. Reassessing received wisdom in ALS pain is common when studied systematically. Eur J Neurol 2012; 19: 531–532. 167. Chio A, Canosa A, Gallo S, et al. Pain in amyotrophic lateral sclerosis: a population-based controlled study. Eur J Neurol 2012; 19: 551–555. 168. Aebischer J, Moumen A, Sazdovitch V, Seilhean D, Meininger V, Raoul C. Elevated levels of IFN+ and LIGHT in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. Eur J Neurol 2012; 19: 752–759. 169. Lo Coco D, La Bella V. Fatigue, sleep, and nocturnal complaints in patients with amyotrophic lateral sclerosis. Eur J Neurol 2012; 19: 760–763. 170. Anand A, Gupta PK, Sharma NK, Prabhakar S. Soluble VEGFR1 (sVEGFR1) as a novel marker of amyotrophic lateral sclerosis (ALS) in the North Indian ALS patients. Eur J Neurol 2012; 19: 788–792. 171. Gargiulo-Monachelli GM, Janota F, Bettini M, Shoesmith CL, Strong MJ, Sica REP. Regional spread pattern predicts survival in patients with sporadic amyotrophic lateral sclerosis. Eur J Neurol 2012; 19: 834–841. 172. Zou ZY, Peng Y, Feng XH, et al. Screening of the FUS gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin. Eur J Neurol 2012; 19: 977–983. 173. Abe K, Ikeda Y, Kurata T, et al. Cognitive and affective impairments of a novel SCA/MND crossroad mutation Asidan. Eur J Neurol 2012; 19: 1070–1078. 174. Pamphlett R. Exposure to environmental toxins and the risk of sporadic motor neuron disease: an expanded Australian case control study. Eur J Neurol 2012; 19: 1343–1348. 175. Bruson A, Sambataro F, Querin G, et al. CAG repeat length in androgen receptor gene is not associated with amyotrophic lateral sclerosis. Eur J Neurol 2012; 19: 1373–1375. 176. Pupillo E, Messina P, Logroscino G, et al. EURALS Consortium. Trauma and amyotrophic lateral sclerosis: a case control study from a population-based registry. Eur J Neurol 2012; 19: 1509–1517. 177. Leonardis L, Dolenc Groıelj L, Vidmar G. Factors related to respiration influencing survival and respiratory function in patients with amyotrophic lateral scle-

© 2013 The Author(s) European Journal of Neurology © 2013 EFNS

1505

rosis: a retrospective study. Eur J Neurol 2012; 19: 1518–1524. 178. Tortelli R, Ruggieri M, Cortese R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol 2012; 19: 1561–1567.

Headache

general

179. Terrazzino S, Tassorelli C, Sances G, et al. Association of haplotype combination of serotonin transporter gene polymorphisms with monthly headache days in MOH patients. Eur J Neurol 2012; 19: 69–75. 180. Steinberg A, Axelsson R, Idestrom L, Muller S, Nilsson Remahl AI. White blood cell SPECT during active period of cluster headache and in remission. Eur J Neurol 2012; 19: 220–225. 181. Linde M, Langnes HA, Hagen K, Bergh K, Stovner LJ. No increase in headache after previous intracranial infections: a historical cohort study (HUNT). Eur J Neurol 2012; 19: 324–331. 182. Esserlind AL, Kirchmann M, Hauge AW, Le H, Olesen J. A genotype phenotype analysis of the 8q22.1 variant in migraine with aura. Eur J Neurol 2012; 19: 603–609. 183. Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 2012; 19: 703–711. 184. Yoon GJ, Kim JT, Chang J, et al. Right-to-left shunts as a cause of juxtacortical spots in patients with migraine. Eur J Neurol 2012; 19: 1086–1092. 185. Mehuys E, Paemeleire K, Van Hees T, et al. Self-medication of regular headache: a community pharmacybased survey. Eur J Neurol 2012; 19: 1093–1099. 186. Ragginer C, Lechner A, Bernecker C, et al. Reduced urinary glutamate levels are associated with the frequency of migraine attacks in females. Eur J Neurol 2012; 19: 1146–1150. 187. Yang Y, Guo ZN, Wu J, et al. Prevalence and extent of right-to-left shunt in migraine: a survey of 217 Chinese patients. Eur J Neurol 2012; 19: 1367–1372. 188. Hagen K, Linde M, Steiner TJ, Zwart JA, Stovner LJ. The bidirectional relationship between headache and chronic musculoskeletal complaints: an 11-year followup in the Nord-Trondelag Health Study (HUNT). Eur J Neurol 2012; 19: 1447–1454.

Epilepsy 189. You G, Huang L, Yang P, et al. Clinical and molecular genetic factors affecting postoperative seizure control of 183 Chinese adult patients with low-grade gliomas. Eur J Neurol 2012; 19: 298–306. 190. Casetta I, Pugliatti M, Faggioli R, et al. Incidence of childhood and adolescence epilepsy: a communitybased prospective study in the province of Ferrara and in Copparo, Italy, 1996 2005. Eur J Neurol 2012; 19: 312–316. 191. Li J, Lin H, Zhu X, et al. Association study of functional polymorphisms in serotonin transporter gene with temporal lobe epilepsy in Han Chinese population. Eur J Neurol 2012; 19: 351–353. 192. Liimatainen S, Peltola J. Epilepsy associated with glutamic acid decarboxylase antibody (GADA). Eur J Neurol 2012; 19: 799.

1506

Editorial

193. Falip M, Carreno M, Miro J, et al. Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. Eur J Neurol 2012; 19: 827–833. 194. Dura-Trave T, Yoldi-Petri ME, Esparza-Estaun J, Gallinas-Victoriano F, Aguilera-Albesa S, Sagastibelza-Zabaleta A. Magnetic resonance imaging abnormalities in children with epilepsy. Eur J Neurol 2012; 19: 1053– 1059. 195. Brigo F, Storti M, Del Felice A, Fiaschi A, Bongiovanni LG. IV valproate in generalized convulsive status epilepticus: a systematic review. Eur J Neurol 2012; 19: 1180–1191. 196. Sierra-Marcos A, Maestro I, Rodriguez-Osorio X, et al. Successful outcome of episodes of status epilepticus after vagus nerve stimulation: a multicenter study. Eur J Neurol 2012; 19: 1219–1223. 197. Phabphal K, Limapichat K, Sathirapanya P, Setthawatcharawanich S, Geater A. Characterization of glucose homeostasis and lipid profile in adult, seizure-free, epileptic patients in Asian population. Eur J Neurol 2012; 19: 1228–1234.

CNS infection 198. Karelis G, Bormane A, Logina I, et al. Tick-borne encephalitis in Latvia 1973 2009: epidemiology, clinical features and sequelae. Eur J Neurol 2012; 19: 62–68. 199. Eikeland R, Ljostad U, Mygland A, Herlofson K, Lohaugen GC. European neuroborreliosis: neuropsychological findings 30 months post-treatment. Eur J Neurol 2012; 19: 480–487. 200. Ponfick M, Hacker S, Gdynia HJ, Linden R, Granz M, Nowak DA. Meningoencephaloradiculomyelitis after tick-borne encephalitis virus infection: a case series. Eur J Neurol 2012; 19: 776–782. 201. Ljostad U, Mygland A. The phenomenon of chronic Lyme; an observational study. Eur J Neurol 2012; 19: 1128–1135. 202. Steiner I, Schmutzhard E, Sellner J, Chaudhuri A, Kennedy PGE. EFNS-ENS guidelines for the use of PCR technology for the diagnosis of infections of the nervous system. Eur J Neurol 2012; 19: 1278–1291.

Peripheral nerve/neuromuscular junction disease 203. Tseng CH, Liao CC, Kuo CM, Sung FC, Hsieh DPH, Tsai CH. Medical and non-medical correlates of carpal tunnel syndrome in a Taiwan cohort of one million. Eur J Neurol 2012; 19: 91–97. 204. Cabrera Serrano M, Rabinstein AA. Usefulness of pulmonary function tests and blood gases in acute neuromuscular respiratory failure. Eur J Neurol 2012; 19: 452–456. 205. Rajabally YA, Lagarde J, Cassereau J, Viala K, Fournier E, Nicolas G. A European multicentre reappraisal of distal compound muscle action potential duration in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol 2012; 19: 638–642. 206. Liu CJ, Chang YS, Teng CJ, et al. Risk of extrathymic cancer in patients with myasthenia gravis in Taiwan: a nationwide population-based study. Eur J Neurol 2012; 19: 746–751. 207. Csuka D, Banati M, Rozsa C, Fust G, Illes Z. High anti-EBNA-1 IgG levels are associated with early-onset myasthenia gravis. Eur J Neurol 2012; 19: 842–846.

208. Heckmann JG, Dutsch M. Recurrent Miller Fisher syndrome: clinical and laboratory features. Eur J Neurol 2012; 19: 944–954. 209. Leonardis L, Auer-Grumbach M, Papi-c L, Zidar J. The N355K atlastin 1 mutation is associated with hereditary sensory neuropathy and pyramidal tract features. Eur J Neurol 2012; 19: 992–998. 210. Hsu WC, Chiu SYH, Yen AMF, et al. Somatic neuropathy is an independent predictor of all- and diabetes-related mortality in type 2 diabetic patients: a population-based 5-year follow-up study (KCIS No. 29). Eur J Neurol 2012; 19: 1192–1198. 211. Gattellari M, Goumas C, Worthington JM. A national epidemiological study of myasthenia gravis in Australia. Eur J Neurol 2012; 19: 1413–1420. 212. Askmark H, Haggard L, Nygren I, Punga AR. Vitamin D deficiency in patients with myasthenia gravis and improvement of fatigue after supplementation of vitamin D3: a pilot study. Eur J Neurol 2012; 19: 1554– 1560. 213. Alblas CL, van Kasteel V, Jellema K. Injection with corticosteroids (ultrasound guided) in patients with an ulnar neuropathy at the elbow, feasibility study. Eur J Neurol 2012; 19: 1582–1584.

Muscle 214. Smits BW, Westeneng HJ, van Hal MA, van Engelen BG, Overeem S. Sleep disturbances in chronic progressive external ophthalmoplegia. Eur J Neurol 2012; 19: 176–178. 215. Shi Z, Hayashi YK, Mitsuhashi S, et al. Characterization of the Asian myopathy patients with VCP mutations. Eur J Neurol 2012; 19: 501–509. 216. Tasca G, Monforte M, Iannaccone E, et al. Muscle MRI in female carriers of dystrophinopathy. Eur J Neurol 2012; 19: 1256–1260. 217. Sansone VA, Ricci C, Montanari M, Apolone G, Rose M, Meola G, INQoL Group. Measuring quality of life impairment in skeletal muscle channelopathies. Eur J Neurol 2012; 19: 1470–1476.

Trauma 218. Vos PE, Alekseenko Y, Battistin L, et al. Mild traumatic brain injury. Eur J Neurol 2012; 19: 191–198. 219. Carpentier AF, Ferrari D, Bailon O, et al. Steroidsparing effects of angiotensin-II inhibitors in glioblastoma patients. Eur J Neurol 2012; 19: 1337–1342.

Neuro-inflammatory diseases 220. Aranyi Z, Kovcs T, Sipos I, Bereczki D. Miller Fisher syndrome: brief overview and update with a focus on electrophysiological findings. Eur J Neurol 2012; 19: 15–e3. 221. Dellavance A, Alvarenga RR, Rodrigues SH, Kok F, de Souza AWS, Andrade LEC. Anti-aquaporin-4 antibodies in the context of assorted immune-mediated diseases. Eur J Neurol 2012; 19: 248–252. 222. Peng F, Yang Y, Liu J, et al. Low antioxidant status of serum uric acid, bilirubin and albumin in patients with neuromyelitis optica. Eur J Neurol 2012; 19: 277– 283. 223. Cossburn M, Tackley G, Baker K, et al. The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol 2012; 19: 655–659.

© 2013 The Author(s) European Journal of Neurology © 2013 EFNS

Editorial

224. Mateen FJ, Zubkov AY, Muralidharan R, et al. Susac syndrome: clinical characteristics and treatment in 29 new cases. Eur J Neurol 2012; 19: 800–811. 225. Cabrera-Gomez JA, Kister I. Conventional brain MRI in neuromyelitis optica. Eur J Neurol 2012; 19: 812– 819. 226. Sahraian MA, Radue EW, Eshaghi A, Besliu S, Minagar A. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis. Eur J Neurol 2012; 19: 1060–1069. 227. Peno IC, , De las Heras Revilla V, et al. Neurobehcet disease: clinical and demographic characteristics. Eur J Neurol 2012; 19: 1224–1227. 228. Gensicke H, Datta AN, Dill P, Schindler C, Fischer D. Increased incidence of Guillain Barre syndrome after surgery. Eur J Neurol 2012; 19: 1239–1244.

Neurology guidelines 229. Straube A, Bronstein A, Straumann D. Nystagmus and oscillopsia. Eur J Neurol 2012; 19: 6–14. 230. Vos PE, Alekseenko Y, Battistin L, et al. Mild traumatic brain injury. Eur J Neurol 2012; 19: 191–198. 231. The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, Hardiman O, Kollewe K, Morrison KE, Petri S, Pradat PF, Silani V, Tomik B, Wasner M, Weber M. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) revised report of an EFNS task force. Eur J Neurol 2012; 19: 360–375. 232. Sorbi S, Hort J, Erkinjuntti T, et al. , the EFNS Scientist Panel on Dementia and Cognitive Neurology. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol 2012; 19: 1159–1179. 233. Steiner I, Schmutzhard E, Sellner J, Chaudhuri A, Kennedy PGE. EFNS-ENS guidelines for the use of PCR technology for the diagnosis of infections of the nervous system. Eur J Neurol 2012; 19: 1278–1291.

© 2013 The Author(s) European Journal of Neurology © 2013 EFNS

1507

234. Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol 2012; 19: 1385–1396. 235. Filippi M, Agosta F, Barkhof F, et al. EFNS task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol 2012; 19: 1487–1501.

Neurology in general 236. Luengo-Fernandez R, Leal J, Gray AM. UK research expenditure on dementia, heart disease, stroke and cancer: are levels of spending related to disease burden? Eur J Neurol 2012; 19: 149–154. 237. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B, on behalf of the CDBE, the European BC. The economic cost of brain disorders in Europe. Eur J Neurol 2012; 19: 155–162. 238. Tsuji S, Mateen FJ. Earthquakes and neurological care. Eur J Neurol 2012; 19: 185–186. 239. Heiss WG. PET in coma and in vegetative state. Eur J Neurol 2012; 19: 207–211. 240. Mitsikostas DD, Chalarakis NG, Mantonakis LI, Delicha EM, Sfikakis PP. Nocebo in fibromyalgia: metaanalysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol 2012; 19: 672–680. 241. Pataka AD, Frangulyan RR, Mackay TW, Douglas NJ, Riha RL. Narcolepsy and sleep-disordered breathing. Eur J Neurol 2012; 19: 696–702. 242. Conte A, Giannantoni A, Proietti S, et al. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity. Eur J Neurol 2012; 19: 725–732. 243. Liu ZH, Tu PH, Pai PC, Chen NY, Lee ST, Chuang CC. Predisposing factors of pituitary hemorrhage. Eur J Neurol 2012; 19: 733–738. 244. Bliwise DL, Trotti LM, Yesavage JA, Rye DB. Periodic leg movements in sleep in elderly patients with Parkinsonism and Alzheimer’s disease. Eur J Neurol 2012; 19: 918–923.

Progress in European neurology 2012-2013.

Progress in European neurology 2012-2013. - PDF Download Free
478KB Sizes 1 Downloads 0 Views